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BACKGROUND
Studies have shown that self-monitoring of blood pressure (BP) is effec-
tive when combined with co-interventions, but its efficacy varies in the 
presence of some co-morbidities. This study examined whether self-
monitoring can reduce clinic BP in patients with hypertension-related 
co-morbidity.
METHODS
A systematic review was conducted of articles published in Medline, 
Embase, and the Cochrane Library up to January 2018. Randomized 
controlled trials of self-monitoring of BP were selected and indi-
vidual patient data (IPD) were requested. Contributing studies 
were prospectively categorized by whether they examined a low/
high-intensity co-intervention. Change in BP and likelihood of un-
controlled BP at 12  months were examined according to number 
and type of hypertension-related co-morbidity in a one-stage IPD 
meta-analysis.
RESULTS
A total of 22 trials were eligible, 16 of which were able to provide IPD 
for the primary outcome, including 6,522 (89%) participants with fol-
low-up data. Self-monitoring was associated with reduced clinic sys-
tolic BP compared to usual care at 12-month follow-up, regardless of 
the number of hypertension-related co-morbidities (−3.12  mm Hg, 
[95% confidence intervals −4.78, −1.46  mm Hg]; P value for interac-
tion with number of morbidities = 0.260). Intense interventions were 
more effective than low-intensity interventions in patients with obesity 
(P < 0.001 for all outcomes), and possibly stroke (P < 0.004 for BP control 
outcome only), but this effect was not observed in patients with coro-
nary heart disease, diabetes, or chronic kidney disease.
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CONCLUSIONS
Self-monitoring lowers BP regardless of the number of hypertension-
related co-morbidities, but may only be effective in conditions such 
obesity or stroke when combined with high-intensity co-interventions.
Keywords:  blood pressure; coronary heart disease; diabetes; hyperten-
sion; obesity; randomized controlled trial; stroke
doi:10.1093/ajh/hpz182
Hypertension is the most common individual condition in 
patients with multi-morbidity.1 Multi-morbidity is defined 
at having two or more concomitant medical conditions and 
affects between 10% and 50% of patients, depending on the 
population studied.1–4 Increasing multi-morbidity is associ-
ated with reduced quality of life.5,6 Due to the complexities 
of studying individuals with multiple conditions, few studies 
have examined interventions specifically designed to im-
prove outcomes in patients with multi-morbidity.7
Optimal management of blood pressure (BP) represents 
the most effective way to prevent stroke and cardiovas-
cular disease.8 Self-monitoring and self-management of BP 
are effective in reducing BP in patients with hypertension.9 
However, in patients with multi-morbidity, it is possible 
that such interventions may be less effective due to clinical 
inertia on the part of the treating physician10,11 or patient 
concerns about self-monitoring in the presence of certain 
co-morbidities.12 Existing studies have failed to show that 
self-management can result in improvement in risk factor 
management in patients with multi-morbidity13,14 and in-
dividual trials usually contain too few individuals with 
multi-morbidity to examine outcomes with adequate power, 
particularly in subgroups.
The BP-SMART collaboration previously carried out 
an individual patient data (IPD) meta-analysis of trials 
examining the efficacy of self-monitoring of BP, including 
data from 25 studies and 8,931 patients.15,16 This anal-
ysis showed reductions in BP with self-monitoring which 
increased with the intensity of co-intervention. However, 
pre-specified subgroup analyses suggested that in some 
individuals with hypertension-related co-morbidity, such as 
stroke or myocardial infarction, this effect may be reduced.15 
To better understand the effect of self-monitoring on clinic 
BP in a population with multi-morbidity, we systematically 
reviewed the literature for new trials and undertook IPD 
meta-analyses by number and type of hypertension-related 
co-morbidities. In contrast to our previous work, the present 
study aimed to account for the modifying effect of intensity 
of co-intervention in analysis of subgroups, which has been 
shown to be important in determining the efficacy of self-
monitoring.15 Hypertension was considered as the illness, 
along with co-morbidities commonly associated with hyper-
tension (coronary heart disease [CHD], stroke [including 
transient ischemic attack], diabetes, chronic kidney disease 
[CKD; defined as stage 3a or above], and obesity [body mass 
index of ≥30 kg/m2]).
METHODS
Study design
This work extends a previous systematic review and IPD 
analysis of self-monitoring of BP in hypertensive patients.15,16 
Searches of the literature were undertaken to identify new 
trials published since the previous review providing data 
on the efficacy of self-monitoring of BP which could be 
combined with data from the original BP-SMART collabo-
ration.15,16 Where available, these data were combined and 
analyzed in a one-stage IPD meta-analysis.
Data sources and searches
A previously published search conducted in Medline, 
Embase, and the Cochrane Library15 was updated to iden-
tify trials examining the efficacy of self-monitoring of BP 
in hypertensive patients, published up to January 2018 
(Supplementary Figure S1).
Study selection
At least two reviewers (KT, RM, and WD) independ-
ently assessed the articles for eligibility and inclusion, 
disagreements were resolved by discussion. All published 
and unpublished controlled trials included in the analysis 
were required to fulfill the following criteria:
• Population: patients with hypertension, not being 
managed as an inpatient.
• Intervention: self-measurement of BP without 
medical professional input plus or minus other 
co-interventions.
• Comparator: no organized self-measurement of BP, 
although there may be some ad hoc measurement 
which would be difficult to prevent or assess.
• Outcome: systolic and/or diastolic BP measured in 
clinic, or by daytime ambulatory measurement.
• Study design: randomized trial of at least 100 
participants followed up for at least 24 weeks (to en-
sure a minimum level of study quality and robustness 
of effect estimates).
• Publication Date: since 2000 (because changes 
in the technology used for self-monitoring make 
comparisons prior to this date less relevant).
All articles were managed and screened using the 
Covidence application (Veritas Health Innovation Ltd, 
Melbourne, Australia).
Data extraction and quality assessment
Corresponding authors whose trials met the inclusion 
criteria were approached for provision of IPD including 
demographic details, antihypertensive medications, life-
style factors, and BP end points (clinic and/or ambula-
tory). All patients had hypertension, and data regarding 
other morbidities were also sought. This analysis focused on 
morbidities commonly associated with hypertension (CHD, 
stroke, diabetes, CKD, and obesity), since recording of such 
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data varied widely across trials and only these conditions 
commonly were captured frequently enough to enable data to 
pooled in this analysis. Where data on even these conditions 
were missing, the morbidity was assumed not to be present 
in the population from that particular study (morbidities 
recorded by each study are listed in Supplementary Table 
S1). Study-level data were extracted from published arti-
cles and checked by the original authors. In particular, any 
co-interventions were carefully documented and prospec-
tively (prior to conducting the analysis) allocated to one of 
four levels of interventional support based on a previous 
classification (Table 1).15–17 Due to limited sample sizes for 
the subgroup analyses planned in the present study, these 
classifications were condensed into two levels (low vs. high 
intensity) (Table 1). Study quality was assessed in terms of 
potential bias from randomization, blinding, outcome as-
sessment, and method of analysis using an adaptation of the 
Cochrane risk of bias tool.15 Original data were kept on a se-
cure server and re-coded to a consistent format across trials, 
where appropriate.
Outcome measures
The primary outcome was change in clinic BP (systolic 
and diastolic) between baseline and 12-month follow-up, 
by number of morbidities. Secondary analyses examined 
the likelihood of uncontrolled BP (as defined by the orig-
inal study; determined by the study population and setting 
[see Supplementary Table S1 for BP targets]) at 12 months by 
number of co-morbidities. All outcomes were also assessed 
at 6-month follow-up. Further analyses explored subgroups 
by type of co-morbidity (in addition to hypertension: CHD, 
stroke, diabetes, CKD, and obesity) and intensity of inter-
vention (high vs. low intensity).
Data synthesis and analysis
Descriptive statistics were used to summarize the baseline 
characteristics of included patients by type of hypertension-
related co-morbidity. The overall impact of self-monitoring 
on BP was assessed in a two-stage IPD meta-analysis. For 
outcomes by co-morbidity, a one-stage IPD meta-analysis 
was conducted with both random intercept and random 
coefficients to account for study-level effects and heteroge-
neity in treatment effects across studies. Linear regression 
was used for continuous outcomes (change in systolic and 
diastolic BP) and logistic regression for binary outcomes 
(odds of uncontrolled BP at follow-up). All analyses were 
conducted by intention-to-treat and each model was adjusted 
for age, sex, baseline clinic BP and level of intervention.
Subgroup analyses were used to examine the effect of self-
monitoring on change in BP and likelihood of uncontrolled 
BP in patients with CHD, stroke, diabetes, CKD, and obesity. 
In each model, the interaction between self-monitoring and 
intensity of co-intervention was explored (high vs. low inten-
sity; defined in Table 1). Sensitivity analyses were conducted 
to examine the impact of missing studies by including 
published aggregate data from those trials which were not 
able to provide IPD for this review. Funnel plots and Egger’s 
test18 were used to assess the potential for publication bias.
All analyses were conducted using STATA version 14.1 
(Special Edition, StataCorp, College Station, TX). Data 
are presented as proportions of the total study popula-
tion, means with standard deviation with 95% confidence 
intervals unless otherwise stated.
Role of the funding source
The funders played no role in the design or execution of 
the study and no role in the preparation of this manuscript. 
The views expressed are those of the author(s) and not nec-
essarily those of the NHS, the NIHR, or the Department of 
Health and Social Care.
RESULTS
The previous literature review identified 36 studies for 
which data from 25 randomized controlled trials were 
obtained.15 The updated search conducted for this analysis 
returned 1,377 new studies (Supplementary Figure S2) and 
after title and abstract screening, 32 full text articles were 
assessed. In total, three new trials were identified as eligible 
for inclusion in the BP-SMART database. Of these, one pro-
vided IPD and the remaining two studies were unable to 
provide data or did not respond (Supplementary Figure S2).
The total dataset included 26 studies published between 
2005 and 2016 including data from 10,713 participants 
(Supplementary Table S1). Data for the primary outcome 
(change in clinic BP at 12  months) were available in 16 
Table 1. Definitions of high- and low-level intensity 
co-interventions
Level Name Description
Low-intensity 
intervention
Level 1 Self-
monitoring 
with minimal 
additional 
contact
Self-monitoring with 
one off educational 
materials and initial 
instructions from a 
nurse.
Level 2 Self-
monitoring 
with 
automated 
feedback or 
support
Web based or 
telephonic tools 
provide feedback 
or support. But no 
regular 1:1 contact. 
High-intensity 
intervention
Level 3 Self-
monitoring 
with an 
active 
intervention
Web based or 
telephonic tools 
provide feedback 
or support and 
education offered in 
regular classes. No 
regular 1:1 contact.
Level 4 Self-
monitoring 
with 
significant 
tailored 
support
Individually tailored 
support from 
study personnel, 
pharmacist or a 
clinician. Could 
include checking 
BP/medication or 
education/lifestyle 
counseling.
This was based on previous work by Uhlig et  al.17 and Tucker 
et al.15
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studies and 7,360 participants, of which 6,522 (88.6%) had 
complete follow-up data and were included in the final anal-
ysis.9,19–42 On average, self-monitoring reduced clinic BP by 
3.11/1.49  mm Hg (systolic/diastolic), although there was 
significant heterogeneity across studies (I2  =  59.6–75.4%, 
P <0.001; Supplementary Figures S3 and S4). Inclusion of 
aggregate data from studies which were not able to pro-
vide IPD did not affect the overall results (Supplementary 
Figure S5). There was no evidence of publication bias among 
studies included in this review (Egger’s test18 = 0.07, P=0.977; 
Supplementary Figure S6).
Patients had between 1 and 6 morbidities (median 2, in-
terquartile range 1.2) including hypertension, which was 
present in all participants (Supplementary Table S2). The 
characteristics of patients with different hypertension-related 
co-morbidities were broadly similar, although patients with 
a history of CHD and stroke were older and those with di-
abetes were more commonly male, with a higher propor-
tion of smokers and were prescribed more BP lowering 
medications at baseline (Supplementary Table S2).
Effect of self-monitoring by number of hypertension-
related co-morbidities
In patients with hypertension but no other hypertension-
related co-morbidities, self-monitoring was associated with 
a 3.80  mm Hg reduction (95% confidence intervals [CI] 
5.84, 1.76  mm Hg) in clinic systolic BP and 1.86  mm Hg 
reduction (95% CI 2.80, 0.92  mm Hg) in clinic diastolic 
BP at 12-month follow-up (Figure 1). The was no differ-
ence in the effectiveness of self-monitoring by increasing 
numbers of co-morbidities (systolic blood pressure P for 
interaction  =  0.260; diastolic blood pressure P for interac-
tion  =  0.079). Self-monitoring of BP was associated with 
reduced odds of having uncontrolled clinic BP at 12-month 
follow-up (OR [odds ratio] 0.68, 95% CI 0.52, 0.87), and 
this was similar in patients with increasing numbers of 
co-morbidities (P for interaction = 0.607). Similar findings 
were observed at 6-month follow-up (Supplementary Figure 
S7).
Effect of self-monitoring by intervention intensity within 
specific morbidities
Self-monitoring was associated with lower clinic sys-
tolic BP in patients with diabetes (−3.71  mm Hg, 95% CI 
−5.76, −1.66 mm Hg) and obesity (−2.81 mm Hg, 95% CI 
−4.94, −0.68 mm Hg), but not patients with CHD, stroke, or 
CKD (Figure 2). There was a significant interaction between 
the effect of self-monitoring and intervention intensity in 
patients with obesity (P value for interaction  =  <0.001) 
(Figure 2). Similar findings were observed for diastolic 
BP (Supplementary Figure S8) and at 6-month follow-up 
(Supplementary Figures S9 and S10).
For patients with diabetes and obesity, self-monitoring 
reduced the likelihood of uncontrolled clinic BP at 12-month 
follow-up (Figure 3). A significant interaction between the 
effect of self-monitoring and intensity of intervention was 
observed in patients with stroke (OR 1.14, 95% CI 0.74–
1.1.76 [low intensity] vs. OR 0.37, 95% CI 0.19–0.70 [high 
intensity]; interaction  =  0.004) and obesity (OR 1.12, 95% 
CI 0.82–1.53 [low intensity] vs. OR 0.49, 95% CI 0.38–0.63 
[high intensity]; interaction  =  <0.001). At 6-month fol-
low-up, self-monitoring was associated with a reduced like-
lihood of uncontrolled clinic BP in patients with diabetes, 
CKD, and obesity (Supplementary Figure S11). In patients 
stroke, diabetes, CKD, and obesity, there was a significant 
interaction between the effect of self-monitoring and in-
tensity of intervention, with those receiving high-intensity 
interventions being less likely to have uncontrolled clinic BP 
at 6-month follow-up.
DISCUSSION
Summary of findings
This is the largest IPD meta-analysis to date of self-
monitoring in hypertension including IPD from 6,522 
patients and 16 trials of self-monitoring of BP in hyper-
tension.9,19–42 Self-monitoring was found to be effective at 
lowering BP,15,17,43 and this effect was observed regardless 
of the number of hypertension-related co-morbidities pre-
sent. This study confirms that self-monitoring is effective 
in patients with obesity.15 In contrast to previous studies, 
there was some limited evidence that patients with stroke 
may benefit from self-monitoring when it is combined with 
a high-intensity co-intervention. Such co-interventions 
might include self-management, pharmacist support, tai-
lored education, and lifestyle counseling. Self-monitoring 
of BP can therefore be recommended as part of a multi-
faceted approach to managing hypertensive patients with 
hypertension-related co-morbidity.
Strengths and weaknesses
This is the largest, and to our knowledge only, IPD meta-
analysis of trials examining the efficacy of self-monitoring 
of BP in hypertensive patients with a hypertension-related 
co-morbidity. Having access to IPD provided a unique 
opportunity to study the effect of self-monitoring within 
specific morbidities, something which is not possible in 
standard meta-analyses.17 As is common in this type of 
review, it was not possible to obtain data from all eligible 
studies, due to inability to make contact with authors, or data 
no longer being held in a format that could be transferred 
across institutions and analyzed. Despite this, complete 
follow-up data were available from 6,522 participants in 
16 studies that provided data on the primary outcome (at 
12-month follow-up). Our sensitivity analyses suggest that 
missing studies would have had little impact on the overall 
association between self-monitoring and BP. Because our 
analyses examined the number and type of hypertension-
related co-morbidity, it was not possible to combine IPD 
with aggregate data from unavailable trials (where patients 
have varying morbidities) to examine the impact of these 
missing data on our hypertension-related co-morbidity 
subgroups.
The focus of this analysis was on the extent to which 
hypertension-related co-morbidity modifies the effect of 
self-monitoring on BP. Co-morbidities were characterized in 
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terms of 6 conditions related to hypertension (hypertension, 
diabetes, CKD, CHD, stroke, and obesity) for which sufficient 
data were available. However, some included studies did not 
collect information about these conditions (see Supplementary 
Table S1 for details), which may have led to an under repre-
sentation of the prevalence of each condition in the study co-
hort. In addition, there are many other co-morbidities that 
can be used to define multi-morbidity1 and may have been 
present in some patients but were not captured as part of the 
original studies contributing data to these analyses.
For the present study, we developed a one-stage ana-
lytical model with study-level random effects for each in-
tervention and control group. In contrast, our previous 
analysis included a single study-level covariate which gave 
less weight to the individual study effects and potentially 
underestimated the between study variance. This change in 
analytical approach had little effect in most of our analyses, 
except that which examined patients with CKD. In that anal-
ysis one study (contributing 15 patients)42 suggested that self-
monitoring increases systolic BP by 41.2 mm Hg, compared 
Figure 1. Effect of self-monitoring on clinic blood pressure at 12-month follow-up by number of hypertension-related co-morbidities (16 studies). 
Blood pressure difference given in mm Hg. Analyses adjusted for age, sex, baseline blood pressure, and level of intervention, with study-level random 
effects for intervention and usual care. Abbreviations: SBP, systolic blood pressure; DBP, diastolic blood pressure; CI, confidence intervals; OR, odds ratio. 
Uncontrolled blood pressure defined by thresholds specified in each contributing study (see Supplementary Table S2 for details).
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to the remaining 7 studies (contributing 292 patients) which 
showed a 5.1  mm Hg reduction at 12-month follow-up. 
Since the present analysis gives more weight to individual 
studies, our combined findings were drawn toward the null 
whereas in our previous paper they were not.15 Such sub-
group analyses, with very small sample sizes and imprecise 
point estimates should be interpreted with caution. Indeed, 
differences between results at 6-month and 12-month fol-
low-up could be explained by the larger number of studies 
and participants available for assessment of outcomes at 
6-month follow-up.
The nature of interventions categorized as high and low in-
tensity were quite heterogeneous and significantly more patients 
and trials would be required to identify exactly which type of 
co-interventions is most effective in which condition. Included 
studies had rates of follow-up which varied between 58% and 
99% with most studies following-up around 90% of participants. 
Our previous analysis using this dataset suggested the impact of 
differential follow-up in individual studies was negligible.15
Studies included in this review used various different meas-
urement protocols for both clinic and home BP readings (e.g., 
number of readings, days, period of rest prior to measure-
ment, etc.). Where individual BP readings were available from 
each included study, the definition of clinic and home BP was 
standardized (clinic BP = mean of the second and third readings; 
home BP = mean of 6 days of readings, after discarding the first 
day’s readings). However, for the majority of studies this standard-
ization was not possible. Whilst this may have affected the abso-
lute values for BP reported in each trial, we do not think this would 
have affected the overall findings, since each randomized group 
were subjected to the same measurement procedures within each 
study. Our analyses also took into account random treatment 
effects across studies, which could include those brought about by 
varying measurement protocols between studies.
Figure 2. Effect of self-monitoring on clinic systolic blood pressure at 12-month follow-up by intervention intensity within specific morbidities. *Two 
studies only provided one patient each to the model. Blood pressure difference given in mm Hg. Analyses adjusted for age, sex, and baseline blood pres-
sure with study-level random effects for intervention and usual care. Abbreviations: sBP, systolic blood pressure; CI, confidence intervals; CHD, coronary 
heart disease; CKD, chronic kidney disease.
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Comparison with previous literature
The efficacy of self-monitoring in patients with multi-
morbidity has been debated, with some studies suggesting it 
may be beneficial,13,14 and others questioning its effectiveness in 
specific morbidities.29 This study confirms the beneficial effects 
of self-monitoring of BP in hypertension-related co-morbidity 
and patients with specific conditions such as obesity and 
demonstrates possible effects in stroke, highlighting the im-
portance of intensity of co-intervention for certain conditions. 
This study is novel in comparison with our previous review15 
due to the inclusion of additional data, better characterization 
of multi-morbidity within studies and updated analysis taking 
into account the intensity of co-intervention within subgroups.
Previous reviews have attempted to define the effects of self-
monitoring as part of a wider self-management intervention, 
in patients with diabetes and CKD,44 and those with previous 
stroke.45 The present analysis included nearly four times as many 
patients with diabetes and/or CKD but was still underpowered to 
show whether self-monitoring is effective at reducing BP when 
combined with co-interventions such as self-management or 
1:1 counseling in patients with specific morbidities. Where more 
data were available at 6-month follow-up, and examining the 
likelihood of uncontrolled BP rather than change in BP, there 
was some evidence to suggest that self-monitoring is effective in 
patients with stroke, diabetes, CKD, and obesity, in combination 
with high-intensity co-interventions. This latter finding was also 
seen in patients with stroke and obesity at 12-month follow-up.
Implications for practice
Many previous studies have considered the impact of 
self-monitoring in hypertension,15 or patients with specific 
morbidities.23,29,40 However in practice, patients present with 
multiple morbidities and so it is important to consider the 
Figure 3. Effect of self-monitoring on likelihood of uncontrolled clinic blood pressure at 12-month follow-up by intervention intensity within specific 
morbidities. *Two studies only provided one patient each to the model. Analyses adjusted for age, sex and baseline blood pressure with study-level 
random effects for intervention and usual care. Abbreviations: OR, odds ratio; CI, confidence intervals; CHD, coronary heart disease; CKD, chronic kidney 
disease. Uncontrolled blood pressure defined by thresholds specified in each contributing study (see Supplementary Table S2 for details).
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efficacy of self-monitoring in the context of multi-morbidity. 
The findings of this review suggest that self-monitoring 
can be recommended as part of a multifaceted approach to 
managing hypertensive patients with hypertension-related 
co-morbidity. There was some variation in the effectiveness 
of self-monitoring within specific morbidities, and this can 
only be partly explained by the use of high- vs. low-intensity 
interventions. However, the present findings suggest that 
where individuals have a history of obesity and possibly 
stroke, self-monitoring is likely to be effective when combined 
with intensive co-interventions such as self-management, 
pharmacist support, tailored education or lifestyle advice. 
Understanding the relative cost effectiveness of the different 
co-interventions is likely to be important when deciding which 
should be encouraged in routine practice. The present analysis 
suggests that targeting individuals with hypertension-related 
co-morbidity is appropriate and this may make the financial 
case for costlier interventions stronger, since patients with 
such co-morbidities are at greater risk of cardiovascular di-
sease.1 Further work should use these IPD to quantify the im-
pact of self-monitoring on outcomes other than BP, as others 
have attempted using aggregated data in previous reviews.45
Self-monitoring of BP leads to clinically significant BP 
reductions in patients with hypertension-related co-morbidity 
and can recommended as part of a wider management plan in 
routine clinical practice. Some limited evidence suggests that 
patients with stroke and/or obesity should be targeted for self-
monitoring interventions that are combined with systematic 
medication titration, pharmacist support, education, or life-
style to maximize the likelihood of BP control at follow-up.
SUPPLEMENTARY MATERIAL
Supplementary data are available at American Journal of 
Hypertension online.
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